Regorafenib (Stivarga)
Revision as of 04:56, 28 September 2012 by PeterYang (talk | contribs) (PeterYang moved page Regorafenib (BAY 73-4506) to Regorafenib (Stivarga): FDA approval)
In clinical trials.
General information
Class/mechanism: Inhibitor of multiple tyrosine kinases, such as: c-Kit, VEGF, BRAF/RAF, RET, PDGFR, which are involved in tumor cell proliferation and survival.[1]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available.